Bienvenue chez Ardeypharm
Études cliniques (anglais)
In vivo effects of mesalazine or E.Coli Nissle 1917 on microsatellite instability in ulcerative colitis.
Goel, A., et al. - Aliment Pharmacol Ther 2009; 30(6): 634-642.this abstract at pubmed.com
Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteers.
Joeres-Nguyen-Xuan , TH, et al. - Inflamm Bowel Dis. 2009; 16(2): 256-262this abstract at pubmed.com
Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study.
Henker, J., et al. - Z Gastroenterol 2008; 46(9): 874-875.this abstract at pubmed.com
Probiotic Escherichia coli Nissle 1917 versus placebo for treating diarrhea of greater than 4 days duration in infants and toddlers.
Henker, J., et al. - Pediatr Infect Dis J 2008; 27(6): 494-499.this abstract at pubmed.com
Influence of E. coli strain Nissle 1917 (EcN) on intestinal gas dynamics and abdominal sensation.
Hernando-Harder, AC, et al. - Dig Dis Sci 2008; 53(2): 443-450.this abstract at pubmed.com
A new approach in pseudomembranous colitis: probiotic Escherichia coli Nissle 1917 after intestinal lavage.
Goerg, K. J., et al. - Eur J Gastroenterol Hepatol 2008; 20(2): 155-156.no abstract available
The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers.
Henker, J., et al. - Eur J Pediatr 2007; 166(4): 311-318.this abstract at pubmed.com
Treatment of irritable bowel syndrome with Escherichia coli strain Nissle 1917 (EcN): a retrospective survey.
Plaßmann, D., et al. - Med Klin 2007; 102 (11): 888-892.this abstract at pubmed.com
Effect of administration of Escherichia coli Nissle (Mutaflor) on intestinal colonisation, endo-toxemia, liver function and minimal hepatic encephalopathy in patients with liver cirrhosis.
Lata, J., et al. - Vnitr Lek 2006; 52 (3): 215-219.this abstract at pubmed.com
Probiotic drug therapy with E. coli strain Nissle 1917 (EcN): results of a prospective study of the records of 3,807 patients.
Krammer, H. J., et al. - Z Gastroenterol 2006; 44: 651-656.this abstract at pubmed.com
Maintaining remission of ulcerative Colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard Mesalazine.
Adam, B., et al. - Z Gastroenterol 2006; 44(3): 267-269.this abstract at pubmed.com
The probiotic E. coli strain Nissle 1917 for the treatment of collagenous colitis: first results of an open-label trial.
Tromm, A., et al. - Z Gastroenterol 2004; 42(5): 365-369.this abstract at pubmed.com
Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.
Kruis, W., et al. - Gut 2004; 53: 1617-1623.this abstract at pubmed.com
The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon.
Fric, P., et al. - Eur J Gastroenterol Hepatol 2003; 15: 313-315.this abstract at pubmed.com
Specific proliferative and antibody responses of premature infants to intestinal colonization with nonpathogenic probiotic E. coli strain Nissle 1917.
Cukrowska, B., et al. - Scand J Immunol 2002; 55: 204-209.this abstract at pubmed.com
Induction and maintenance of remission with nonpathogenic Escherichia coli in patients with pouchitis.
Kuzela, L., et al. - Am J Gastroenterol 2001; 96(11): 3218-3219.this abstract at pubmed.com
Successful treatment of gut-caused halitosis with a suspension of living non-pathogenic Escherichia coli bacteria-a case report.
Henker, J., et al. - Eur J Pediatr 2001; 160(10): 592-594.this abstract at pubmed.com
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.
Rembacken, B. J., et al. - Lancet 1999; 354: 635-639.this abstract at pubmed.com
Prophylaxis of polymorphous light eruption: Comparative efficacy of bacteria, E. coli strain Nissle 1917, and Nicotinamide/ Folic Acid.
Wurzel, R. M. - [German] Aktuel Dermatol 1999; 25: 329-333.no abstract available
Probiotic therapy of pseudomembranous colitis. Combination of intestinal lavage and oral administration of Escherichia coli.
Goerg, K. J., et al. - [German] DMW 1998; 123: 1274-1278.this abstract at pubmed.com
Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis.
Kruis, W., et al. - Aliment Pharmacol Ther 1997; 11(5): 853-858.this abstract at pubmed.com
Crohn's Disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease?
Malchow, H. - J Clin Gastroenterol 1997; 25: 653-658.this abstract at pubmed.com
Effect of preventive administration of a nonpathogenic Escherichia coli strain on the colonization of the intestine with microbial pathogens in newborn infants.
Lodinová-Zádníková, R., et al. - Biol Neonate 1997; 71(4): 224-232.this abstract at pubmed.com
Colonization of adults by an apathogenic E. coli strain administered after gut decontamination.
Malchow, H., et al. - Gastroenterology 1995; 108 (Suppl): A-869.no abstract available
Treatment of chronic constipation with physiologic Escherichia coli bacteria. Results of a clinical study of the effectiveness and tolerance of microbiological therapy with the E. coli Nissle 1917 strain (Mutaflor).
Möllenbrink, M., et al. - [German] Med Klin 1994, 89: 587-593.this abstract at pubmed.com
Chronic Constipation. Comparison of microbiological and lactulose treatment.
Bruckschen, E., et al. - [German] MMW 1994; 16: 241-245.this abstract at pubmed.com
Local and serum antibody response in fullterm and premature infants after artificial colonization of the intestine with E. coli strain Nissle 1917 (Mutaflor).
Lodinová-Zádníková, R., et al. - Pediatr Allergy Immunol 1992; 3: 43-48.no abstract available
The treatment of intestinal diseases with Mutaflor. A multicenter retrospective study.
Schütz, E. - [German] Fortschr Med 1989; 107: 599-602.this abstract at pubmed.com